Justin B. Echouffo-Tcheugui, Sabra C. Lewsey, Robert G. Weiss
Title and authors | Publication | Year |
---|---|---|
The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD+ Therapy in HFpEF
Koay YC, McIntosh B, Ng YH, Cao Y, Wang XS, Han Y, Tomita S, Bai AY, Hunter B, Misra A, Loughrey CM, Bannon PG, Lal S, Lusis AJ, Kaye DM, Larance M, O\u2019Sullivan JF |
Circulation Research | 2025 |
Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review
Santos Guzmán MV, Rivera D, Reyna Guerrero IM, Fernandez Rodriguez AL, Azcona R, Escobar Batista D, Montano Diaz G, García Zuluaga LC, Santos Rosario V |
Cureus | 2025 |
Cardiac Substrate Utilization and Relationship to Invasive Exercise Hemodynamic Parameters in HFpEF
O\u2019Sullivan JF, Li M, Koay YC, Wang XS, Guglielmi G, Marques FZ, Nanayakkara S, Mariani J, Slaughter E, Kaye DM |
JACC: Basic to Translational Science | 2024 |
Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain
Schauer A, Adams V, Kämmerer S, Langner E, Augstein A, Barthel P, Männel A, Fabig G, Alves PK, Günscht M, El-Armouche A, Müller-Reichert T, Linke A, Winzer EB |
Circulation. Heart failure | 2024 |
Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
De Lorenzi AB, Kaplinsky E, Zambrano MR, Chaume LT, Rosas JM |
Drugs in Context | 2023 |
Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF).
Valero-Muñoz M, Saw EL, Hekman RM, Blum BC, Hourani Z, Granzier H, Emili A, Sam F |
Frontiers in Cardiovascular Medicine | 2022 |
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction.
Brust-Sisti L, Rudawsky N, Gonzalez J, Brunetti L |
2022 |